Baidu
map

Nat Commun:科学家发现乳腺癌扩散的罪魁祸首“高胆固醇”,确定新的药物靶点

2017-10-13 佚名 medicalxpress

高胆固醇水平与乳腺癌扩散到身体其他部位有关,但医生和研究人员并不知道这一联系的原因。伊利诺伊大学(UniversityofIllinois)的一项新的研究发现,罪魁祸首是胆固醇代谢的副产品,它作用于特定的免疫细胞,从而促进癌细胞的扩散,而不是阻止癌细胞扩散。


A cholesterol byproduct facilitates breast cancer's spread by hijacking immune cells, a new University of Illinois study found. Pictured, from left: Postdoctoral researcher Amy Baek, professor Erik Nelson and breast cancer survivor Sarah Adams. Credit: L. Brian Stauffer

胆固醇水平与乳腺癌扩散到身体其他部位有关,但医生和研究人员并不知道这一联系的原因。伊利诺伊大学(UniversityofIllinois)的一项新的研究发现,罪魁祸首是胆固醇代谢的副产品,它作用于特定的免疫细胞,从而促进癌细胞的扩散,而不是阻止癌细胞扩散。

发表在《自然通讯》(NatureCommunications)杂志上的这项研究发现了新的潜在的药物靶标,可以抑制危险胆固醇副产物的产生或作用,一种叫做27HC的分子。

乳腺癌的影响是非常大的,在8个妇女中至少有一个患有乳腺癌。我们已经制定了很好的治疗方法,但是很多女性会经历转移性乳腺癌,当乳腺癌扩散到其他器官时,在这一点上我们真的没有有效的治疗方法。我们想要找出是什么推动了这个过程,以及我们是否可以用药物来对付它,”分子和整合生理学教授埃里克·尼尔森(ErikNelson)说。

纳尔逊的小组给患有乳腺癌的老鼠喂食高胆固醇的食物。研究人员证实,高水平的胆固醇会增加肿瘤的生长和转移,而使用降胆固醇药物治疗的小鼠则有更少的转移。然后他们更进一步,特别抑制了在胆固醇代谢过程中产生27HC的酶。

“通过抑制制造27HC的酶,我们发现抑制因子对乳腺癌的转移作用。”这项研究表明,针对这种酶的药物治疗可能是一种有效的治疗方法,”艾米·贝克(AmyBaek)说。

研究人员还发现特定免疫细胞(某些类型的中性粒细胞和t细胞)在27HC的转移位点上的异常活动。

“通常情况下,你身体的免疫系统有能力攻击癌症,”尼尔森说,“但是我们发现27HC在免疫细胞上工作,让他们误以为癌症对自己的身体没伤害。”反而它劫持了免疫系统来帮助癌症扩散。

因为27HC通过免疫系统,而不是在乳腺癌本身,研究人员相信他们的发现对实体肿瘤有广泛的适用性。他们对结肠癌肺癌、黑素瘤和胰腺癌进行了实验,发现了27HC对所有肿瘤类型的转移都有抑制作用,这表明针对27HC的治疗可以在多种癌症类型中有效。

研究人员正在努力进一步了解27HC对免疫细胞的影响。在UrbanaCarleFoundationHospital的临床合作伙伴中,研究小组正在努力确定27HC是否和小鼠一样在人类患者中有同样的途径。

“我们希望开发小分子药物来抑制27HC,”尼尔森说。与此同时,市面上有很好的降胆固醇药物:他汀类药物。患高胆固醇的癌症患者可能想和他们的医生谈谈。

原始出处:

Amy E. Baek, Yen-Rei A. Yu, Sisi He, et.al. The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nature Communications 8, Article number: 864 (2017)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882518, encodeId=73721882518fa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 22 12:55:00 CST 2018, time=2018-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802470, encodeId=4fd318024e0c7, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Mar 27 00:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087151, encodeId=b90b208e1515e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 08 06:55:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384939, encodeId=22541384939c7, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Oct 14 23:55:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252495, encodeId=ee5a25249592, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Fri Oct 13 09:09:37 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
    2018-06-22 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882518, encodeId=73721882518fa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 22 12:55:00 CST 2018, time=2018-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802470, encodeId=4fd318024e0c7, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Mar 27 00:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087151, encodeId=b90b208e1515e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 08 06:55:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384939, encodeId=22541384939c7, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Oct 14 23:55:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252495, encodeId=ee5a25249592, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Fri Oct 13 09:09:37 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882518, encodeId=73721882518fa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 22 12:55:00 CST 2018, time=2018-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802470, encodeId=4fd318024e0c7, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Mar 27 00:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087151, encodeId=b90b208e1515e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 08 06:55:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384939, encodeId=22541384939c7, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Oct 14 23:55:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252495, encodeId=ee5a25249592, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Fri Oct 13 09:09:37 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
    2018-09-08 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1882518, encodeId=73721882518fa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 22 12:55:00 CST 2018, time=2018-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802470, encodeId=4fd318024e0c7, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Mar 27 00:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087151, encodeId=b90b208e1515e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 08 06:55:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384939, encodeId=22541384939c7, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Oct 14 23:55:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252495, encodeId=ee5a25249592, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Fri Oct 13 09:09:37 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
    2017-10-14 xugc
  5. [GetPortalCommentsPageByObjectIdResponse(id=1882518, encodeId=73721882518fa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 22 12:55:00 CST 2018, time=2018-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802470, encodeId=4fd318024e0c7, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Mar 27 00:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087151, encodeId=b90b208e1515e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 08 06:55:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384939, encodeId=22541384939c7, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Oct 14 23:55:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252495, encodeId=ee5a25249592, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Fri Oct 13 09:09:37 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
    2017-10-13 1e0e5697m83(暂无匿称)

    henhao

    0

相关资讯

乳腺癌荧光示踪前哨淋巴结活组织检查操作指南

癌细胞通过淋巴管转移至淋巴结是乳腺癌局部区域扩散的主要方式。通过手术切除腋窝淋巴结确定的腋窝淋巴结分期是乳腺癌预后判断和辅助治疗决策的重要依据。传统的腋窝淋巴结清扫可以获得准确的转移淋巴结数目和良好的局部控制,但上肢水肿、神经损伤等并发症长期困扰着医师和患者。前哨淋巴结活组织检查(简称活检) 相对微创、并发症少,而接受前哨淋巴结活检与清扫手术的患者的局部控制率和远期生存率无明显差异,目前已经成为临

Environ Res:研究揭示乳腺癌的一大重要诱发因素!

根据迄今为止对人类研究的最全面的综述,暴露于环境化学品,特别是生命早期,是乳腺癌发展的重要因素。研究结果可以帮助预防旨在减少疾病发病率的战略,因为全球的发病率继续增加。

粉红丝带月|乳腺癌诊疗需引入“全程管理”

相较于上个世纪70年代,乳腺癌早已不是一种罕见病。乳腺癌在一线大城市的患病比率节节攀升。多年来,乳腺癌在北、上、广等一线发达城市,始终位居女性十大高发恶性肿瘤之榜首,目前已经达到60/10万。过往,我们始终把聚焦点放在治疗环节,较少地关注预防、康复以及心理疏导等方面。事实上,随着乳腺癌诊疗技术的发展,乳腺癌的疗效越来越好,实现治愈的患者数量越来越多,许多患者都能获得长期生存。乳腺癌已经不是人们眼中

不仅是乳腺癌,科学家有望开发特定“抗癌细菌”!

乳腺癌是妇女常见的高发性癌症之一,每8个妇女中有1个罹患。10月5日在线发表在Oncotarget杂志上的研究拓宽了“人体微生物组”研究的新视野,首次证实在乳腺组织中存在“微生物组”,并在乳腺癌中起作用。借助这项发现,科学家或将找到快速诊断乳腺癌的生物标志物,并开发出特定的抗癌细菌。

Autophagy:星形胶质细胞通过KISS1调节自噬促进乳腺癌转移到大脑的进展。

转移灶的形成,是乳腺癌(BrCa)进展中的一个重要阶段。KISS1 的表达与转移进展受到抑制相关。最近,作者的研究表明,BrCa 转移到大脑时在mRNA和蛋白水平都只有低水平的KISS1表达。

Oncotarget:乳腺癌患者具有不同的乳腺微生物群

乳腺癌是在全球妇女中最常见的癌症,但是至今为止,至少有一半的患病妇女没有已知的危险因素。只有一部分患者因为乳腺癌遗传倾向,或是暴露于已知的环境危险因素而患病。因此,我们还需要进一步确定其他的乳腺癌危险因素。

Baidu
map
Baidu
map
Baidu
map